Events | 2016.09.16
Semaglutide reduced major cardiovascular events by 26% in adults with type 2 diabetes at high cardiovascular risk
MUNICH, September 16, 2016 /PRNewswire/ -- This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced that semaglutide, an investigational glucagon-like peptide-1 (GLP-1)...
For more information, please visit
http://www.prnewswire.com/news-releases/[...]iovascular-risk-593658161.html
